Clinical Trial Search

Primary: Overall Duration of Follow-up Care to Evaluate Overall Effectiveness of the Use of the Coflex® Interlaminer Technology — 201.26; 191.75 days

Primary: Two-Years Survival Rate — 33.98; 34.09 Percentage of Participants — p=0.5059

Primary: Number of Participants With Uterine Extension of Hysterotomy — 3; 4 Participants

Primary: Parental Anxiety — 4.2; 3.9 points on a scale

Primary: Number of Participants Stratified as Non-Index Culprit Lesion Related Major Adverse Cardiac Events (NC-MACE) or No NC-MACE and Association With maxLCBI4mm as a…

Primary: Number of Participants With Composite Compliance With Expected Infection Prevention Practices Upon Entry to Contact Precaution-patient Rooms — 1297; 954 Participants

Primary: Time-Weighted Sum of Pain Relief Rating and Pain Intensity Difference Scores From 0 to 8 Hours (SPRID 0-8) — 5.0; 30.8; 29.6; 31.7 units on a scale — p=<0.001

Primary: Recruitment Rate (Percentage of Potentially Eligible Participants Who Were Enrolled to the Study) — 20.3 percentage of participants

Primary: Percent Change in Area of Thyroid Nodules — -19.98; -9.31 percentage change — p=0.047

Primary: Image Quality Scores Using Likert Scale — 3.3; 3.5; 3.4; 3.5 units on a scale

Primary: Number of Participants With Clinically Significant Change From Baseline in Physical Examination Findings — 0 Participants

Primary: Risk of Fatal Coronary Event or Non-fatal MI — 27.0; 26.3 percent risk of major cv event in 10 yrs — p=0.50

Primary: Change From Baseline to 4 Week Endpoint in Weekly Mean of Daily 24-Hour Average Pain Scores (APS) — -0.90; -1.20 units on a scale

Primary: Number of Participants With Adverse Events — 7; 29 Participants

Primary: Radiological Assessments of Marginal Bone Level Alteration — 0.02; -0.18 millimeter